Abbvie Inc Common Stock (ABBV) 66.57 $ABBV 4 Biotech

New Post Public Reply Private Reply Replies (0) Message Board

Aug 3, 2016 at 9:01 PM

Abbvie Inc Common Stock (ABBV) 66.57 $ABBV

4 Biotech Stocks Poised to Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 3:18PM CDT
Notwithstanding the sector declines, things appear far better now than they did a quarter ago for the biotech sector.
BIIB: 321.34 (-8.77), BMRN: 101.46 (+2.39), GILD: 80.09 (+0.52), AMGN: 173.43 (-0.72), ABBV: 66.57 (-0.21), ARIA: 9.93 (+0.21), AEGN: 19.19 (-0.96)

Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
Sheraz Mian - Zacks Investment Research - Mon Aug 01, 2:21PM CDT
Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
KO: 43.64 (+0.11), MCK: 195.14 (+1.61), NWL: 53.51 (-0.31), ABBV: 66.57 (-0.21), APD: 148.21 (-0.02), UNP: 92.87 (+1.57), MS: 28.42 (+0.42)

Company News for August 01, 2016
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:10AM CDT
Companies in the News are: XRX,MRK,ABBV,EXPE
MRK: 57.65 (-0.68), EXPE: 112.56 (-0.99), ABBV: 66.57 (-0.21), XRX: 9.94 (+0.13)

What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 79.66 (+2.75), BIIB: 321.34 (-8.77), ABT: 44.95 (-0.12), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), PFE: 35.29 (-1.10), SGNT: 21.71 (-0.03), ABBV: 66.57 (-0.21), PRTA: 58.27 (+2.66), NVS: 82.40 (-0.56)

AbbVie (ABBV) Beats on 2Q Earnings, Revenues, Ups View
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 9:44AM CDT
AbbVie (ABBV) raised its 2016 outlook following its Q2 earnings and revenue beat.
JNJ: 123.90 (-0.95), ABBV: 66.57 (-0.21), LLY: 82.72 (-0.60), BMY: 74.80 (-0.25)

Q2 GDP Disappoints, Q2 Earnings Mixed Ahead of Bell: XOM, CVX, UPS, ABBV, BCS
Mark Vickery - Zacks Investment Research - Fri Jul 29, 8:55AM CDT
Both GDP results and Exxon's (XOM) earnings for Q2 were below expectations. Who outperformed the consensus before the bell Friday?
BCS: 8.05 (+0.21), XOM: 87.49 (+0.45), ABBV: 66.57 (-0.21), CVX: 100.61 (+1.02), UPS: 108.29 (+0.83)

AbbVie (ABBV) Tops 2Q Earnings & Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:58AM CDT
AbbVie (ABBV) surpassed expectations in Q2 and raised its outlook for the year.
ABBV: 66.57 (-0.21)

AbbVie Reports Second-Quarter 2016 Financial Results
PR Newswire - Fri Jul 29, 6:38AM CDT
AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2016.
ABBV: 66.57 (-0.21)

AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
PR Newswire - Thu Jul 28, 4:30PM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial to study the safety and efficacy of venetoclax in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and have received one to three prior lines of therapy. The combination of venetoclax, bortezomib and dexamethasone will be compared to treatment with bortezomib, dexamethasone and placebo.1 Bortezomib, a proteasome inhibitor, and dexamethasone, a corticosteroid, are both common therapies used to treat symptomatic multiple myeloma.3
ABBV: 66.57 (-0.21)

The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 321.34 (-8.77), GILD: 80.09 (+0.52), AMGN: 173.43 (-0.72), ABBV: 66.57 (-0.21), CELG: 116.14 (+1.85)

2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 321.34 (-8.77), JNJ: 123.90 (-0.95), GILD: 80.09 (+0.52), MRK: 57.65 (-0.68), AMGN: 173.43 (-0.72), ABBV: 66.57 (-0.21)

Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 321.34 (-8.77), VRTX: 100.44 (+1.30), GILD: 80.09 (+0.52), ALXN: 137.66 (+4.05), AMGN: 173.43 (-0.72), ABBV: 66.57 (-0.21), CELG: 116.14 (+1.85)

Amgen and Daiichi Sankyo Team Up for Biosimilars in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 9:16AM CDT
Amgen (AMGN) inked an exclusive agreement with Daiichi Sankyo for the commercialization of nine biosimilars in Japan.
AMGN: 173.43 (-0.72), ABBV: 66.57 (-0.21), NVS: 82.40 (-0.56)

The Zacks Analyst Blog Highlights: Juno, Amgen, AbbVie, Gilead and CytRx
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 8:30AM CDT
The Zacks Analyst Blog Highlights: Juno, Amgen, AbbVie, Gilead and CytRx
GILD: 80.09 (+0.52), CYTR: 0.61 (+0.04), AMGN: 173.43 (-0.72), ABBV: 66.57 (-0.21), JUNO: 31.31 (+0.63)

Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing
Arpita Dutt - Zacks Investment Research - Wed Jul 13, 2:17PM CDT
Immuno-oncology focused Juno (JUNO) remained in the news with the FDA first placing a clinical hold on a pivotal study and then removing it.
BIIB: 321.34 (-8.77), GILD: 80.09 (+0.52), CYTR: 0.61 (+0.04), ALXN: 137.66 (+4.05), AMGN: 173.43 (-0.72), ABBV: 66.57 (-0.21), JUNO: 31.31 (+0.63)

Testosterone Replacement Therapy (TRT) Market to Face Lean Patch until 2024 as it Inches Close to Patent Cliff, Says TMR
PR Newswire Europe - Tue Jul 12, 11:31AM CDT
ALBANY, New York, July 12, 2016 /PRNewswire/ --
AGN: 252.53 (+1.78), ENDP: 18.21 (+1.10), LLY: 82.72 (-0.60), ABBV: 66.57 (-0.21)

AbbVie's ABT-414 Gets Rare Pediatric Disease Status in U.S.
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 9:19AM CDT
AbbVie's (ABBV) ABT-414 has been granted Rare Pediatric Disease Designation in the U.S. for the treatment of pediatric patients with EGFR-amplified DIPG.
INVA: 13.01 (+0.17), GWPH: 95.02 (+0.95), SGEN: 49.01 (+0.49), ABBV: 66.57 (-0.21)

Amgen Humira Biosimilar Briefing Documents Look Good
Arpita Dutt - Zacks Investment Research - Mon Jul 11, 7:04AM CDT
An FDA advisory panel will be meeting tomorrow to review Amgen Inc.'s (AMGN) ABP 501, a biosimilar version of AbbVie's Humira.
INVA: 13.01 (+0.17), FCSC: 1.07 (+0.03), AMGN: 173.43 (-0.72), ABBV: 66.57 (-0.21)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navigating Career Growth Beyond Job Titles at Webinar

Hasn't it ever struck you that job titles often fence people in like some unwanted corral, keeping potential tightly leashed? Well, here's something that might shake up your thoughts a tad. University of Phoenix is teeing up a webinar titled "Beyond The Job Title: Finding Purpose and Recognizing the Value You Bring." Scheduled for October 15, 2026, this is all about...

Zenni and Chase Stokes Foster Student Wellbeing in NYC

Picture this: near 300 high schoolers milling around, glancing through shiny new glasses from the Zenni x Chase Stokes collection. In the heart of New York City, these kids are getting a double-dose of care that's all too rare—free vision screenings paired with mental health support. It's the kind of collaboration that shows you what's possible when a company, an actor,...

India's Women Apparel Market Grows Amid Innovation

India's Women Apparel Market on the Rise The winds of fashion change are sweeping through India, and the women's apparel market is at the heart of this sartorial hurricane. Set to explode from USD 28,786.82 million in 2024 to USD 45,491.96 million by 2032, this market is turning heads with a compound annual growth rate (CAGR) of 5.21%. What's stirring this pot, you ask?...

2026 Leica Oskar Barnack Awards Spotlight Global Talent

Winners Redefine Photography's Boundaries in 2026 Photographers are like modern-day storytellers, freezing moments in time and weaving visual narratives that provoke thought—or at least that's what the folks behind the Leica Oskar Barnack Award (LOBA) seem to believe. This year's ceremony upped the ante, not just handing out glittering prizes and shiny cameras, but...

Bill Evans Enhances Gateway's Wealth Management Expertise

Welcome Aboard, Bill Evans Some days the financial world throws a gem your way, something worth more than a rat-race racehorse in a shattered stock rally. Meet Bill Evans, a seasoned professional stepping into the vibrant arena of Gateway Financial Partners. He’s put in 29 years around the investment block, and now he’s parking himself in Glastonbury, Connecticut, set...

Mastering Packaging Costs: Beyond the Box Price

Peeling Back the Layers of Packaging Costs Packaging's a bit like an onion—every layer you peel back reveals another cost you didn’t see at first glance. Folks in the know, like Kyle Reger of Jamestown Container Companies, are flipping the script on how we approach packaging expenses. It's not just about snagging the cheapest box on the shelf anymore. There's a whole...

TKO's Bold $2B All-Cash Move for SVC's Hotels

TKO's Big, Bold Bid: What Does it Mean? In the crazy world of high-stakes hospitality investments, there are moments that turn heads. TKO's $2 billion all-cash offer to snag Service Properties Trust's prized hotel portfolio is exactly one of those shake-ups. Let's not sugarcoat it; this is a bold move to the big leagues, and it's not without its quirks. A Cash-Infused...

NCICU's Digital Boost for NC Transfer Students

New Platform Eases the Transfer Struggle They’ve finally cooked up something good for the college crowd in North Carolina. The NCICU, with the NCCCS, has rolled out a platform called Transfer Pathways to simplify students' path from two-year to four-year schools. This ain't just a tweak—it's backed by a hefty $2 million in grants. Hats off to those...

AI Visibility: A Game Changer for SEO in 2027?

AI Changes the SEO Game Rank Math, the brains behind a trusty WordPress SEO plugin, has thrown a bold prediction at us: AI visibility is set to become a standard SEO metric next year. Gurugram, India, saw this gem of an announcement on October 9, 2026. So, what's ticking here? Consumers, more than ever, are resting on AI-generated answers to make decisions. It's like...

CellFiber Expands to Philly: Boosting US Biotech Scene

CellFiber's Leap into 'Cellicon Valley' Folks, when the biotech winds start blowing, you better have your sails up. CellFiber Co., Ltd., a Tokyo-based innovator, has landed itself a comfy spot in the City of Brotherly Love. We're talking Philadelphia, folks, or, as it's dubbed in certain circles, 'Cellicon Valley.' Now if that's not a name that screams biotech pedigree, I...